Literature DB >> 26847611

Neuron specific enolase: a promising therapeutic target in acute spinal cord injury.

Azizul Haque1, Swapan K Ray2, April Cox3, Naren L Banik3,4.   

Abstract

Enolase is a multifunctional protein, which is expressed abundantly in the cytosol. Upon stimulatory signals, enolase can traffic to cell surface and contribute to different pathologies including injury, autoimmunity, infection, inflammation, and cancer. Cell-surface expression of enolase is often detected on activated macrophages, microglia/macrophages, microglia, and astrocytes, promoting extracellular matrix degradation, production of pro-inflammatory cytokines/chemokines, and invasion of inflammatory cells in the sites of injury and inflammation. Inflammatory stimulation also induces translocation of enolase from the cytosolic pool to the cell surface where it can act as a plasminogen receptor and promote extracellular matrix degradation and tissue damage. Spinal cord injury (SCI) is a devastating debilitating condition characterized by progressive pathological changes including complex and evolving molecular cascades, and insights into the role of enolase in multiple inflammatory events have not yet been fully elucidated. Neuronal damage following SCI is associated with an elevation of neuron specific enolase (NSE), which is also known to play a role in the pathogenesis of hypoxic-ischemic brain injury. Thus, NSE is now considered as a biomarker in ischemic brain damage, and it has recently been suggested to be a biomarker in traumatic brain injury (TBI), stroke and anoxic encephalopathy after cardiac arrest and acute SCI as well. This review article gives an overview of the current basic research and clinical studies on the role of multifunctional enolase in neurotrauma, with a special emphasis on NSE in acute SCI.

Entities:  

Keywords:  Inflammation; Major histocompatibility complex (MHC); Matrix metalloproteinase (MMP); Neuron specific enolase (NSE); Neuronal death; Plasmin; Spinal cord injury (SCI)

Mesh:

Substances:

Year:  2016        PMID: 26847611      PMCID: PMC4864119          DOI: 10.1007/s11011-016-9801-6

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  84 in total

1.  Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients.

Authors:  Neng-Yao Shih; Hsing-Liang Lai; Gee-Chen Chang; Hsien-Chih Lin; Yu-Chung Wu; Jacqueline M Liu; Ko-Jiunn Liu; Szu-Wen Tseng
Journal:  Jpn J Clin Oncol       Date:  2010-04-15       Impact factor: 3.019

2.  α-Enolase Causes Proinflammatory Activation of Pulmonary Microvascular Endothelial Cells and Primes Neutrophils Through Plasmin Activation of Protease-Activated Receptor 2.

Authors:  Ashley Bock; Nicole Tucker; Marguerite R Kelher; Samina Y Khan; Eduardo Gonzalez; Max Wohlauer; Kirk Hansen; Monika Dzieciatkowska; Angels Sauaia; Anirban Banerjee; Ernest E Moore; Christopher C Silliman
Journal:  Shock       Date:  2015-08       Impact factor: 3.454

3.  Spinal cord injury-induced expression of the immune-regulatory chemokine interleukin-16 caused by activated microglia/macrophages and CD8+ cells.

Authors:  Christian A Mueller; Hermann J Schluesener; Sabine Conrad; Torsten Pietsch; Jan M Schwab
Journal:  J Neurosurg Spine       Date:  2006-03

Review 4.  The microanatomy of spinal cord injury: a review.

Authors:  Martin M Mortazavi; Ketan Verma; Olivia A Harmon; Christoph J Griessenauer; Nimer Adeeb; Nicholas Theodore; R Shane Tubbs
Journal:  Clin Anat       Date:  2014-07-11       Impact factor: 2.414

5.  Structural biomarkers in the cerebrospinal fluid within 24 h after a traumatic spinal cord injury: a descriptive analysis of 16 subjects.

Authors:  M H Pouw; B K Kwon; M M Verbeek; P E Vos; A van Kampen; C G Fisher; J Street; S J Paquette; M F Dvorak; M C Boyd; A J F Hosman; H van de Meent
Journal:  Spinal Cord       Date:  2014-04-08       Impact factor: 2.772

6.  Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase.

Authors:  Roser López-Alemany; Colin Longstaff; Stephen Hawley; Massoud Mirshahi; Pere Fábregas; Merce Jardí; Elizabeth Merton; Lindsey A Miles; Jordi Félez
Journal:  Am J Hematol       Date:  2003-04       Impact factor: 10.047

7.  Neuron-specific enolase increases in plasma during and immediately after extracorporeal circulation.

Authors:  P Johnsson; S Blomquist; C Lührs; G Malmkvist; C Alling; J O Solem; E Ståhl
Journal:  Ann Thorac Surg       Date:  2000-03       Impact factor: 4.330

8.  Neuron-specific enolase is a marker of cerebral ischemia and infarct size in rat cerebrospinal fluid.

Authors:  H G Hårdemark; L Persson; H G Bolander; L Hillered; Y Olsson; S Påhlman
Journal:  Stroke       Date:  1988-09       Impact factor: 7.914

Review 9.  Biomarkers in spinal cord injury.

Authors:  M H Pouw; A J F Hosman; J J van Middendorp; M M Verbeek; P E Vos; H van de Meent
Journal:  Spinal Cord       Date:  2009-01-20       Impact factor: 2.772

10.  Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing.

Authors:  U Schönbeck; F Mach; P Libby
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

View more
  28 in total

1.  Targeting Enolase in Reducing Secondary Damage in Acute Spinal Cord Injury in Rats.

Authors:  Azizul Haque; Mollie Capone; Denise Matzelle; April Cox; Naren L Banik
Journal:  Neurochem Res       Date:  2017-05-15       Impact factor: 3.996

2.  Advances in Multiplexed Paper-Based Analytical Devices for Cancer Diagnosis: A Review of Technological Developments.

Authors:  Nihan Yonet-Tanyeri; Benjamin Z Ahlmark; Steven R Little
Journal:  Adv Mater Technol       Date:  2021-04-21

3.  Role of Neuron-Specific Enolase in the Diagnosis and Disease Monitoring of Sarcoidosis.

Authors:  Noriaki Sunaga; Yasuhiko Koga; Yoshimasa Hachisu; Koichi Yamaguchi; Masaki Aikawa; Norimitsu Kasahara; Yosuke Miura; Hiroaki Tsurumaki; Masakiyo Yatomi; Reiko Sakurai; Toshitaka Maeno; Takeshi Hisada
Journal:  Can Respir J       Date:  2022-05-26       Impact factor: 2.130

4.  Axonal damage is remarkable in patients with acutely worsening symptoms of compression myelopathy: biomarkers in cerebrospinal fluid samples.

Authors:  Hiroshi Takahashi; Yasuchika Aoki; Arata Nakajima; Masato Sonobe; Fumiaki Terajima; Masahiko Saito; Takuya Miyamoto; Keita Koyama; Keiichiro Yamamoto; Takeo Furuya; Masao Koda; Seiji Ohtori; Masashi Yamazaki; Koichi Nakagawa
Journal:  Eur Spine J       Date:  2018-03-19       Impact factor: 3.134

5.  Enolase and Acute Spinal Cord Injury.

Authors:  Rachel Polcyn; Mollie Capone; Azim Hossain; Denise Matzelle; Naren L Banik; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2017-12-29

Review 6.  Brain Monitoring in Critically Neurologically Impaired Patients.

Authors:  Salazar Jones; Gary Schwartzbauer; Xiaofeng Jia
Journal:  Int J Mol Sci       Date:  2016-12-27       Impact factor: 5.923

7.  Growth and Differentiation of Circulating Stem Cells After Extensive Ex Vivo Expansion.

Authors:  Silvia Barbon; Senthilkumar Rajendran; Thomas Bertalot; Monica Piccione; Marco Gasparella; Pier Paolo Parnigotto; Rosa Di Liddo; Maria Teresa Conconi
Journal:  Tissue Eng Regen Med       Date:  2021-02-24       Impact factor: 4.169

Review 8.  Glucose metabolic crosstalk and regulation in brain function and diseases.

Authors:  Shuai Zhang; Brittany Bolduc Lachance; Mark P Mattson; Xiaofeng Jia
Journal:  Prog Neurobiol       Date:  2021-06-10       Impact factor: 10.885

9.  Meta-analysis of neuron specific enolase in predicting pediatric brain injury outcomes.

Authors:  Babak Nakhjavan-Shahraki; Mahmoud Yousefifard; Alireza Oraii; Arash Sarveazad; Mostafa Hosseini
Journal:  EXCLI J       Date:  2017-07-03       Impact factor: 4.068

10.  Metabolic syndrome and its components with neuron-specific enolase: a cross-sectional study in large health check-up population in China.

Authors:  Shu-Yi Wang; Xiao-Juan Zha; Xin-Ying Zhu; Wen-Bo Li; Jun Ma; Ze-Wei Wu; Huan Wu; Ming-Fei Jiang; Yu-Feng Wen
Journal:  BMJ Open       Date:  2018-04-10       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.